ABBV-744 IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER (NSCLC) OPTIONS

In Phase A, members will get diverse doses and schedules of oral ABBV-744 tablet to identify safe dosing program. Added members might be enrolled with the identified monotherapy dosign routine. In Segment B, members will obtain oral ruxolitinib and ABBV-744 will probably be given as "add-on" therapy. In Section C, participants will obtain ABBV-744